CRM vs. ATRA

Last updated Jun 13, 2026

CRM (Salesforce, Inc.) and ATRA (Atara Biotherapeutics, Inc.) are both stocks. CRM operates in Software - Application (Technology), while ATRA operates in Biotechnology (Healthcare). Over the past 10 years, CRM returned 7.60%/yr vs -31.94%/yr for ATRA. At a 0.26 correlation, their price movements are largely independent.

Performance

CRM vs. ATRA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Salesforce, Inc. (CRM) and Atara Biotherapeutics, Inc. (ATRA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, CRM achieves a -37.06% return, which is significantly higher than ATRA's -42.45% return. Over the past 10 years, CRM has outperformed ATRA with an annualized return of 7.60%, while ATRA has yielded a comparatively lower -31.94% annualized return.

CRM

• 1D: -0.34%
• 1M: 0.29%
• YTD: -37.06%
• 6M: -36.31%
• 1Y: -37.22%
• 3Y*: -6.88%
• 5Y*: -6.82%
• 10Y*: 7.60%

ATRA

• 1D: -0.48%
• 1M: -0.67%
• YTD: -42.45%
• 6M: -42.15%
• 1Y: 19.52%
• 3Y*: -42.05%
• 5Y*: -50.77%
• 10Y*: -31.94%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CRM vs. ATRA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CRM Salesforce, Inc.	-37.06%	-20.25%	27.76%	98.46%	-47.83%	14.20%	36.82%	18.74%	33.98%	49.33%
ATRA Atara Biotherapeutics, Inc.	-42.45%	35.91%	3.82%	-84.37%	-79.19%	-19.71%	19.19%	-52.59%	91.93%	27.46%

Correlation

The correlation between CRM and ATRA is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.14
Correlation (3Y) Calculated over the trailing 3-year period	0.17
Correlation (5Y) Calculated over the trailing 5-year period	0.25
Correlation (10Y) Calculated over the trailing 10-year period	0.27
Correlation (All Time) Calculated using the full available price history since Oct 16, 2014	0.26

The correlation between CRM and ATRA shifts across timeframes, from 0.14 (1 year) to 0.27 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap CRM : $144.49B ATRA : $146.58M
EPS CRM : $8.59 ATRA : -$0.72
PS Ratio CRM : 3.62 ATRA : 6.06
Total Revenue (TTM) CRM : $42.83B ATRA : $22.62M
Gross Profit (TTM) CRM : $33.25B ATRA : $21.73M
EBITDA (TTM) CRM : $12.32B ATRA : -$6.92M

Return for Risk

CRM vs. ATRA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRM

CRM Risk / Return Rank: 6
CRM Sharpe Ratio Rank: 6
CRM Sortino Ratio Rank: 8
CRM Omega Ratio Rank: 9
CRM Calmar Ratio Rank: 4
CRM Martin Ratio Rank: 2

ATRA

ATRA Risk / Return Rank: 56
ATRA Sharpe Ratio Rank: 47
ATRA Sortino Ratio Rank: 65
ATRA Omega Ratio Rank: 70
ATRA Calmar Ratio Rank: 49
ATRA Martin Ratio Rank: 48

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRM vs. ATRA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Salesforce, Inc. (CRM) and Atara Biotherapeutics, Inc. (ATRA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	CRM	ATRA	Difference
Sharpe ratio: Return per unit of total volatility	-0.98	0.14	-1.12
Sortino ratio: Return per unit of downside risk	-1.38	1.38	-2.75
Omega ratio: Gain probability vs. loss probability	0.84	1.22	-0.38
Calmar ratio: Return relative to maximum drawdown	-0.95	0.25	-1.20
Martin ratio: Return relative to average drawdown	-1.78	0.44	-2.23

CRM vs. ATRA - Sharpe Ratio Comparison

The current CRM Sharpe Ratio is -0.98, which is lower than the ATRA Sharpe Ratio of 0.14. The chart below compares the historical Sharpe Ratios of CRM and ATRA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

CRM vs. ATRA - Drawdown Comparison

The maximum CRM drawdown since its inception was -70.50%, smaller than the maximum ATRA drawdown of -99.74%. Use the drawdown chart below to compare losses from any high point for CRM and ATRA.

Drawdown Indicators

	CRM	ATRA	Difference
Max Drawdown Largest peak-to-trough decline	-70.50%	-99.74%	+29.24%
Max Drawdown (1Y) Largest decline over 1 year	-39.36%	-76.89%	+37.53%
Max Drawdown (3Y) Largest decline over 3 years	-54.70%	-92.76%	+38.06%
Max Drawdown (5Y) Largest decline over 5 years	-58.62%	-99.16%	+40.54%
Max Drawdown (10Y) Largest decline over 10 years	-58.62%	-99.68%	+41.06%
Current Drawdown Current decline from peak	-54.33%	-99.35%	+45.02%
Average Drawdown Average peak-to-trough decline	-16.15%	-74.03%	+57.88%
Ulcer Index Depth and duration of drawdowns from previous peaks	20.92%	44.08%	-23.16%

Volatility

CRM vs. ATRA - Volatility Comparison

The current volatility for Salesforce, Inc. (CRM) is 16.76%, while Atara Biotherapeutics, Inc. (ATRA) has a volatility of 21.61%. This indicates that CRM experiences smaller price fluctuations and is considered to be less risky than ATRA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CRM	ATRA	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.76%	21.61%	-4.85%
Volatility (6M) Calculated over the trailing 6-month period	31.59%	131.62%	-100.03%
Volatility (1Y) Calculated over the trailing 1-year period	38.09%	143.90%	-105.81%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	37.07%	121.99%	-84.92%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	35.38%	100.19%	-64.81%

Dividends

CRM vs. ATRA - Dividend Comparison

CRM's dividend yield for the trailing twelve months is around 1.28%, while ATRA has not paid dividends to shareholders.

Position	TTM	2025	2024
ATRA Atara Biotherapeutics, Inc.	0.00%	0.00%	0.00%
CRM Salesforce, Inc.	1.28%	0.63%	0.48%

Financials

Frequently Asked Questions

Can I hold both CRM and ATRA in my portfolio?

CRM and ATRA have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, CRM or ATRA?

ATRA has higher volatility (21.61%) compared to CRM (16.76%). In terms of maximum drawdown, CRM dropped -70.50% vs ATRA's -99.74%.

Which has better risk-adjusted returns?

ATRA currently has the higher Sharpe Ratio (0.14 vs -0.98), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.